Serviks Kanserinde Timokinon ve Etoposid Kombinasyonunun Hücre Canlılığı Üzerine Etkileri
Göster/ Aç
Tarih
2022Yazar
Çelebioğlu, Hediye Gamze Nur
Ambargo Süresi
Acik erisimÜst veri
Tüm öğe kaydını gösterÖzet
. Cervical
cancer is the second most common type of cancer in women, after breast cancer, that
causes the death of a woman every two minutes in the world. Major treatment options
include surgery, radiotherapy, and chemotherapy. Etoposide, a topoisomerase-II
inhibitor, is an effective chemotherapeutic agent in the treatment of lung cancer,
testicular cancer, acute myelogenous leukemia and acute myelomonocytic leukemia,
Hodgkin lymphoma and high-grade non-Hodgkin lymphoma, and cervical cancer.
Research focuses on the discovery of innovative drug strategies to improve treatment
outcomes. In alternative and complementary medicine, the positive effects of plants in
cancer treatment have been the focus of attention and studies have begun to increase.
In many studies, it has been suggested that thymoquinone, which is isolated from
Nigella sativa species in the Ranunculacea family known as "çörek otu", has
anticarcinogenic, cardioprotective, anti-inflammatory, analgesic, antioxidant, immune
system strengthening effects. Studies on the efficacy of thymoquinone together with
etoposide in cervical cancer are insufficient. In this study, it was aimed to evaluate the
effect of combinations with thymoquinone on etoposide cytotoxicity in cervical cancer
cell line (HeLa cell) by MTT method. Compared to the negative control,
thymoquinone significantly decreased cell viability in a dose-dependent manner at the
concentrations of 250 μM and above for 24 hours incubation and 125 μM and above
for 48 hours incubation, and the IC50 value were 233.6 μM and 145.5 μM,
respectively, in HeLa cells. The IC50 values of etoposide in HeLa cells were 167.3
μM and 52.7 μM at 24 and 48 hours of exposure, respectively. Thymoquinone
significantly decreased the approximate IC50 value of etoposide in doses of 15.63 μM
and above for 24 hours incubation and 31.5 μM and above for 48 hours incubation in
a dose-dependent manner. Our results showed that thymoquinone can increase the
cytotoxic effect of etoposide in cancer cell, which suggests that etopside may increase
its anticancer effect, however comprehensive studies are needed on this subject. This
study is a preliminary study and will contribute to the development of new treatment
strategies.